Latest From Poxel SA
Enanta hoped its Phase II study would indicate a better efficacy and/or tolerability profile for EDP-305 compared to other FXR agonists for NASH, including Intercept’s OCA. Despite the inconclusive data, it plans a longer Phase IIb study.
Dainippon Sumitomo suffers major Phase III setback for one of its key oncology prospects, and although the former Boston Biomedical asset will carry on in other planned indications, the Japanese firm may have to look for ways to fill the gap.
Partners Poxel and Sumitomo Dainippon confirm Japan filing plans for novel glimin antidiabetic following positive top-line Phase III results, and cast an eye towards market positioning.
Having previously disclosed in an SEC filing that it acquired a commercial product, Mylan announces it bought TOBI Podhaler for $463m. Biohaven completes second licensing deal with AstraZeneca, while struggling United Therapeutics and MannKind team up.
- Therapeutic Areas
- Hepatic (Liver)
- Metabolic Disorders
- Western Europe
- Parent & Subsidiaries
- Poxel SA
- Senior Management
Thomas Kuhn, CEO
Anne Renevot, CFO
Noan Beerman, EVP, Bus. Dev. & Pres., US Operations
Pascale Malgouyres, EVP, Commercial Dev.
Iman Barilero, PhD, SVP & Global Head, Reg. Affairs
David E Moller, MD, CSO
- Contact Info
Phone: (33) 437 372 012
259-261 avenue Jean Jaurès
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.